Choroidal Neovascularization – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Choroidal Neovascularization – Drugs In Development, 2024 report and make more profitable business decisions.
Choroidal neovascularization (CNV) involves the growth of new blood vessels that originate from the choroid, the pigmented vascular layer of tissue behind the retina. Symptoms include painless loss of vision, metamorphopsia, and color disturbances. Treatment includes anti-vascular endothelial growth factor (anti-VEGF) agents, laser photocoagulation, and photodynamic therapy.
The Choroidal Neovascularization drugs in development market research report provide comprehensive information on the therapeutics under development for Choroidal Neovascularization, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Choroidal Neovascularization and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Choroidal Neovascularization | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 36 molecules, with 30 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Choroidal Neovascularization therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Choroidal Neovascularization pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Choroidal Neovascularization treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Alvotech SAAsclepiX Therapeutics Inc
Avirmax Inc
CdmoGen Co Ltd
Chinese Academy of Sciences
Chugai Pharmaceutical Co Ltd
Clearside BioMedical Inc
Disc Medicine Inc
F. Hoffmann-La Roche Ltd
Genentech USA Inc
Iconic Therapeutics Inc
Innovent Biologics Inc
Isarna Therapeutics GmbH
Laboratoires Thea SA
Luye Pharma Group Ltd
Mabion SA
National Eye Institute
NovelMed Therapeutics Inc
NutriForward LLC
Oceanyx Pharmaceuticals Inc
Ocuphire Pharma Inc
Palatin Technologies Inc
RemeGen Co Ltd
SEASUN THERAPEUTICS Inc
Skyline Therapeutics (Shanghai) Co Ltd
Sun Pharmaceutical Industries Ltd
Sylentis SAU
Uni-Bio Science Group Ltd
Unity Biotechnology Inc
University of Melbourne
University of Utah
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Choroidal Neovascularization reports